RNS Number : 6866M
Kromek Group PLC
25 May 2022

25 May 2022

Kromek Group plc
("Kromek" or the "Group")

Kromek receives new Nuclear Security order from US federal entity
Repeat order received for D3S-ID 'dirty bomb' detector

Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that it has received an order from a US federal entity for the Group's D3S-ID wearable nuclear radiation detector. The order is worth $695,000 and is to be delivered in the coming months. This is a repeat order for the D3S-ID from this customer, following the award of a $1.6m two-year contract in September 2021.

The D3S-ID is designed to enable first responders, armed forces, border security and other CBRN experts to detect radiological threats such as dirty bombs, radioactive contamination and smuggling of radioactive substances. It is a wearable gamma neutron RIID (radioisotope identification device) that the Group believes is one of the fastest and most accurate isotope identification devices in its class on the market. Kromek's D3S platform - comprising the Group's range of D3S products - is widely deployed as a networked solution to protect cities, buildings, or critical infrastructure.

Dr Arnab Basu, CEO of Kromek, said: "We're pleased to have received this latest order for our D3S-ID nuclear radiation detector that provides security authorities with an early warning system for potential threats. Being awarded a repeat order for this product from this important customer is a great endorsement. With the volatility of the current geopolitical environment, we are receiving heightened demand for our CBRN solutions, from new and existing customers, as governments become increasingly aware of the need to enhance their real-time threat monitoring. We believe that our solutions are best placed to provide them with this capability and, accordingly, we expect to receive further orders for our nuclear security products in the near term."

For further information, please contact:

Kromek Group plc
Arnab Basu, CEO — +44 (0)1740 626 060
Paul Farquhar, CFO

finnCap Ltd (Nominated Adviser and Broker)
Geoff Nash/Kate Bannatyne/George Dollemore - Corporate Finance — +44 (0)20 7220 0500
Tim Redfern/Charlotte Sutcliffe - ECM

Luther Pendragon (Financial PR)
Harry Chathli/Claire Norbury — +44 (0)20 7618 9100

About Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

Further information is available at www.kromek.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFZLLLLELZBBE